Systemic lupus erythematosus after mesotherapy with acetyl-L-carnitine [1]

Journal of Clinical Rheumatology

Volumn 12, Issue 5, 2006, Pages 261-262

  Colón Soto, Marilú ^a   Peredo, Rubén A ^a   Vilá, Luis M ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; LEVACECARNINE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHENYTOIN; PREDNISONE;

ADULT; ARTHRALGIA; BRAIN INFARCTION; CASE REPORT; CHRONIC GLOMERULONEPHRITIS; CLINICAL FEATURE; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HOMEOPATHY; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; LETTER; MACULOPAPULAR RASH; MALAISE; MALAR RASH; MESOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OLIGURIA; PLEURITIC CHEST PAIN; PRIORITY JOURNAL; RASH; SEIZURE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN;

ACETYLCARNITINE; ADULT; AUTOIMMUNE DISEASES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OBESITY; VITAMIN B COMPLEX;

EID: 33749526734     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000239831.84504.0b     Document Type: Letter

References (10)

1. D'Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett. 2000;15:421-432.
2. Cooper GS, Parks CG. Occupational and environmental exposures as risk factors for systemic lupus erythematosus. Curr Rheumatol Rep. 2004;6:367-374.
3. Cossarizza A, Mussini C, Mongiardo N, et al. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS. 1997;11:19-26.
4. Di Marzio L, Moretti S, D'Alo S, et al. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effects on lymphocyte apoptosis and ceramide generation. Clin Immunol. 1999;92:103-110.
5. De Simone C, Famularo G, Tzantozoglou S, et al. Carnitine depletion in peripheral blood mononuclear cells from patients with AIDS: effects of oral L-carnitine. AIDS. 1994;8:655-660.
6. Jirillo E, Altamura M, Munno I, et al. Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-α levels in patients with active pulmonary tuberculosis. Immunopharmacol Immunotoxicol. 1991;13:135-146.
7. Nagore E, Ramos P, Botella-Estrada R, et al. Cutaneous infection with Mycobacterium fortuitum after localized microinjections (mesotherapy) treated successfully with a triple drug regimen. Acta Dermatol Venereol. 2001;81:291-293.
8. Rosina P, Chieregato C, Miccolis D, et al. Psoriasis and side-effects of mesotherapy. Int J Dermatol. 2001;40:581-583.
9. Dyck DJ. Dietary fat intake, supplements, and weight loss. Can J Appl Physiol. 2000;25:495-523.
10. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci. 2004;1033:99-107.